HLF:NYSEHerbalife Ltd. Analysis

Herbalife Ltd. (HLF) is trading at $13.94, which sits below its 20‑day SMA of $14.89 and 50‑day SMA of $16.42, indicating short‑term weakness, while remaining above the 200‑day SMA of $11.96, suggesting a longer‑term floor. The RSI of 36.5 points to a mildly oversold condition, but the bearish MACD histogram reinforces downward momentum, and volume has been trending lower, hinting at waning buying interest. Support sits near $13.57 with resistance at $16.92, and the stock’s 30‑day volatility is a lofty 49%, underscoring a high‑risk price environment. Fundamentally, HLF appears cheap with a trailing P/E of 6.3 and a forward P/E of 4.6, far below the sector average, while its gross margin of 78% and operating margin of 8.3% demonstrate solid profitability. The DCF‑derived fair value of roughly $24.5 suggests substantial upside, though the market’s current target median of $16 only reflects an 18% upside. Cash on hand ($353M) covers less than a fifth of total debt ($2.18B), and a negative book value per share leads to a negative P/B ratio, flagging balance‑sheet concerns. Despite these risks, the company enjoys strong cash flow generation ($247.7M free cash flow) and has attracted notable institutional interest, including a multi‑million‑share stake by Baupost Group and endorsement from billionaire Seth Klarman. Overall, the stock sits at a valuation discount in a defensive consumer‑staples niche, but technical weakness and balance‑sheet headwinds temper enthusiasm.